Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase IIb clinical trial of RPT904 for food allergy

Next Previous
Trial Profile

Phase IIb clinical trial of RPT904 for food allergy

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 18 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs RPT 904 (Primary)
  • Indications Food hypersensitivity
  • Focus Therapeutic Use

Most Recent Events

  • 15 Apr 2025 According to RAPT Therapeutics media release, Brian Wong will be instrumental in advancing RPT904 to a Phase 2b clinical trial for food allergy in the second half of 2025 and generating important data to differentiate RPT904 as an attractive therapeutic option for patients.
  • 06 Mar 2025 According to RAPT Therapeutics media release, company expect to initiate a Phase 2b clinical trial for RPT904 in food allergy in the second half of 2025 and await clinical data later this year from company's partner Jemincare to guide our development strategy in CSU.
  • 27 Dec 2024 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top